GSK plc (GSK) Earnings History
Annual and quarterly earnings data from 1990 to 2025
Loading earnings history...
GSK EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
GSK Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 72.4% | 25.5% | 17.5% |
| 2024 | 71.2% | 12.8% | 8.2% |
| 2023 | 71.8% | 22.2% | 16.2% |
| 2022 | 67.4% | 21.9% | 51.0% |
| 2021 | 66.9% | 17.6% | 17.8% |
Download Data
Export GSK earnings history in CSV or JSON format
Free sign-in required to download data
GSK plc (GSK) Earnings Overview
As of May 6, 2026, GSK plc (GSK) reported trailing twelve-month net income of $6.40B, reflecting +348.4% year-over-year growth. The company earned $3.14 per diluted share over the past four quarters, with a net profit margin of 17.5%.
Looking at the long-term picture, GSK's 5-year EPS compound annual growth rate (CAGR) stands at +14.2%, showing solid earnings momentum. The company achieved its highest annual net income of $14.96B in fiscal 2022.
GSK plc maintains industry-leading profitability with a gross margin of 72.4%, operating margin of 25.5%, and net margin of 17.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including AZN ($10.39B net income, 17.5% margin), NVS ($13.53B net income, 25.6% margin), SNY ($7.81B net income, 16.7% margin), GSK has outperformed on profitability metrics. Compare GSK vs AZN →
GSK Earnings vs Peers
Earnings metrics vs comparable public companies
GSK Historical Earnings Data (1990–2025)
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.72B | +122.0% | $8.34B | $5.56 | 17.5% | 25.5% |
| 2024 | $2.58B | -47.7% | $4.02B | $1.24 | 8.2% | 12.8% |
| 2023 | $4.93B | -67.1% | $6.75B | $2.40 | 16.2% | 22.2% |
| 2022 | $14.96B | +241.1% | $6.43B | $2.40 | 51.0% | 21.9% |
| 2021 | $4.38B | -23.7% | $4.36B | $2.70 | 17.8% | 17.6% |
| 2020 | $5.75B | +23.8% | $5.98B | $2.86 | 23.6% | 24.6% |
| 2019 | $4.64B | +28.2% | $6.96B | $2.32 | 13.8% | 20.6% |
| 2018 | $3.62B | +136.5% | $5.48B | $1.82 | 11.8% | 17.8% |
| 2017 | $1.53B | +68.0% | $4.09B | $0.78 | 5.1% | 13.5% |
| 2016 | $912M | -89.2% | $2.60B | $0.46 | 3.3% | 9.3% |
Full GSK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See GSK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GSK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GSK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGSK — Frequently Asked Questions
Quick answers to the most common questions about buying GSK stock.
Is GSK growing earnings?
GSK EPS is $3.14, with earnings growth accelerating to +348.4%. This exceeds the 5-year CAGR of +14.2%. TTM net income reached $6.4B.
What are GSK's profit margins?
GSK plc net margin is +17.5%, with operating margin at +25.5%. Above-average margins indicate pricing power.
How consistent are GSK's earnings?
GSK earnings data spans 1990-2025. The accelerating earnings trend is +348.4% YoY. Historical data enables comparison across business cycles.